deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01028716

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Sponsor: Fred Hutchinson Cancer Center

Conditions Acute Biphenotypic Leukemia Acute Erythroid Leukemia in Remission Acute Leukemia in Remission Acute Lymphoblastic Leukemia in Remission Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome Acute Myeloid Leukemia With FLT3/ITD Mutation Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1 Acute Myeloid Leukemia With Multilineage Dysplasia Acute Myeloid Leukemia With t(6;9) Acute Myeloid Leukemia in Remission Acute Undifferentiated Leukemia Adult Acute Lymphoblastic Leukemia in Complete Remission B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1) Blasts Under 5 Percent of Bone Marrow Nucleated Cells Burkitt Lymphoma Childhood Acute Lymphoblastic Leukemia in Complete Remission DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma Hematopoietic Cell Transplant Recipient Myelodysplastic Syndrome Ph+ ALL Recurrent Anaplastic Large Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma Secondary Acute Myeloid Leukemia T Lymphoblastic Lymphoma
Interventions Cyclophosphamide Filgrastim Fludarabine Phosphate Mycophenolate Mofetil Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Peripheral Blood Stem Cell Transplantation Tacrolimus Total-Body Irradiation
Updated 16 times since 2017 Last updated: Jan 4, 2023 Started: May 19, 2010 Primary completion: Oct 7, 2021 Completion: Oct 7, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study experienced lower accrual rates after the onset of COVID. Upon review of the collected data it was deemed that an adequate amount of subjects has been enrolled to date to assess study aims.

Other terminated trials from Fred Hutchinson Cancer Center

See all terminations from Fred Hutchinson Cancer Center

A PHASE2 clinical study on Acute Biphenotypic Leukemia and Acute Erythroid Leukemia in Remission, this trial is terminated or withdrawn. The trial is conducted by Fred Hutchinson Cancer Center and has accumulated 16 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Apr 2019 · 4 months · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Aug 2020 · 11 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Feb 2023 · 9 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. May 2022 — Feb 2023 [monthly]

    Terminated PHASE2

  5. Mar 2022 — May 2022 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

▶ Show 11 earlier versions

  1. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  2. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Sep 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  6. Apr 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Dec 2018 — Apr 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  9. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations